Commentary: Keep Medicine Out of the US-China Tech War

Novel medicines can’t be treated in the same zero-sum way as semiconductors or electric vehicles, where one competitor’s win comes at the expense of the other, says Juliana Liu for Bloomberg Opinion.As Washington and Beijing tussle for dominance in frontier technologies, there’s one area in which competition shouldn’t preclude collaboration: innovative medicines. Beijing’s latest five-year plan for the biotechnology sector details how the country wants to lead the field globally. Unusually for an industrial blueprint, it comes with numeric targets. By 2030, Chinese drugmakers are expected to have made a “major leap” in competitiveness with sales of new medications growing...